On Mar 09, 2026, MGNX reported earnings of -0.23 USD per share (EPS) for Q4 25, beating the estimate of -0.29 USD, resulting in a 22.40% surprise. Revenue reached 41.23 million, compared to an expected 23.10 million, with a 78.50% difference. The market reacted with a -1.73% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.54 USD, with revenue projected to reach 15.95 million USD, implying an increase of 134.78% EPS, and decrease of -61.32% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Omeros Corporation
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.58
Actual
$0.98
Surprise
+268.56%
Tilray Brands, Inc. Common Stock
Report Date
Apr 01, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.24
Surprise
-68.07%
FitLife Brands, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.21
Actual
$0.16
Surprise
-25.22%
Neogen Corp
Report Date
Apr 09, 2026 For Q3 26
Estimate
$0.05
Actual
$0.09
Surprise
+53.32%
IM Cannabis Corp. Common Shares
Report Date
Mar 30, 2026 For Q4 25
Estimate
$0.12
Actual
-$1.19
Surprise
-1055.53%
FAQ
What were MacroGenics, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, MacroGenics, Inc. reported EPS of -$0.23, beating estimates by 22.4%, and revenue of $41.23M, 78.5% above expectations.
How did the market react to MacroGenics, Inc.'s Q4 2025 earnings?
The stock price moved down -1.73%, changed from $1.73 before the earnings release to $1.70 the day after.
When is MacroGenics, Inc. expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for MacroGenics, Inc.'s next earnings report?
Based on 6
analysts, MacroGenics, Inc. is expected to report EPS of -$0.54 and revenue of $15.95M for Q1 2026.